MiR-100 regulates cell viability and apoptosis by targeting ATM in pediatric acute myeloid leukemia

Area of Science:

• Molecular Biology
• Oncology
• Pediatric Hematology

Background:

• Acute myeloid leukemia (AML) is a prevalent pediatric cancer with significant mortality.
• MicroRNA-100 (miR-100) has been implicated in the progression of various diseases, including AML.
• Understanding the molecular mechanisms of miR-100 in pediatric AML is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the molecular mechanisms of miR-100 in pediatric acute myeloid leukemia (AML).
• To explore the relationship between miR-100 and the ataxia telangiectasia mutated (ATM) gene in AML.
• To assess the impact of miR-100 and ATM on AML cell viability and apoptosis.

Main Methods:

• Quantitative reverse transcription polymerase chain reaction (qRT-PCR) and western blot assays to measure miR-100 and ATM expression.
• MTT assay for cell viability assessment and flow cytometry for apoptosis measurement.
• Bioinformatic prediction (mirtarbase) and luciferase reporter assays to confirm miR-100 targeting of ATM.

Main Results:

• miR-100 was significantly upregulated in pediatric AML patient bone marrow and cell lines.
• Knockdown of miR-100 inhibited cell viability and promoted apoptosis in AML cell lines (Kasumi-1, MV-4-11).
• ATM was downregulated in AML, and miR-100 directly targeted ATM's 3' untranslated region (3'UTR), showing a negative correlation.

Conclusions:

• miR-100 plays a critical role in regulating cell viability and apoptosis in pediatric AML by targeting ATM.
• The miR-100/ATM axis represents a potential therapeutic target for pediatric AML.
• Restoring ATM expression or inhibiting miR-100 may offer novel treatment strategies for pediatric AML.